Half-life

168 h

Tmax

—

Category

peptide

CJC-1295 with DAC incorporates a drug affinity complex that covalently attaches to albumin, extending its plasma half-life to approximately 7 days. This modification allows once-weekly dosing while maintaining continuous GHRH receptor stimulation. The DAC form produces sustained GH pulse amplification over days, which differs significantly from the pulsatile profile of non-DAC GHRH analogues. The extended half-life means longer washout periods if side effects occur. Systematic tracking of GH-related symptoms, injection site reactions, and concomitant compound timing is particularly important for this long-acting peptide.

Mechanism

A GHRH analog bearing a drug-affinity complex (DAC) that binds albumin to substantially extend its half-life. Like other GHRH analogs, it stimulates the GHRH receptor to promote growth-hormone release.

Research summary

Studied as a long-acting GHRH analog in early clinical pharmacology work. It is not an FDA-approved therapeutic, and long-term human outcome data are limited.

Reported side effects

Reported effects include injection-site reactions, flushing, and headache. Sustained elevation of growth hormone and IGF-1 is a monitoring consideration in a clinical context. The full profile is not established.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

CJC-1295 with DAC pharmacology study · Journal of Clinical Endocrinology & Metabolism (2006)search PubMed for CJC-1295 DAC growth hormone
GHRH analog reviews · peer-reviewed review articles (2015)class context

References

CJC-1295 with DAC PK studyDOI: 10.1210/jc.2005-1536

TrackPep er en loggføringsapp. Den registrerer det du logger, og anbefaler eller beregner aldri mengder.